TYRA BIOSCIENCES, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 49
- Market Cap
- $1.1B
- Website
- http://www.tyra.bio
- Introduction
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SN?P, enables the rapid and precise refinement of structural design through iterative molecular SN?Pshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300
Tyra Biosciences appoints Dr. Erik Goluboff as SVP, Clinical Development, to lead TYRA-300's Phase 2 trial for IR NMIBC, following FDA IND clearance. TYRA-300, an FGFR3-selective inhibitor, aims to offer better-tolerated treatment options, with patient dosing in SURF302 expected by Q2 2025.
FDA Clears NMIBC Agent TYRA-300 for Phase 2 Trial
The FDA cleared TYRA-300's IND application for low-grade, intermediate-risk NMIBC, enabling a phase 2 trial. TYRA-300, an oral FGFR3-selective inhibitor, targets cancer and skeletal dysplasia. The SURF302 trial will assess its efficacy and safety in FGFR3-altered NMIBC patients, with dosing starting in Q2 this year.
Tyra Falls on FDA Nod
Tyra Biosciences' shares fell as the FDA cleared its IND application for TYRA-300, enabling a Phase 2 trial in IR NMIBC. TYRA-300, an FGFR3-selective inhibitor, aims to minimize toxicities and targets FGFR3 mutations prevalent in NMIBC. Dr. Erik Goluboff leads the program, with TYRA-300 also set for trials in pediatric ACH and mUC.
Tyra Biosciences, Inc. Receives IND Clearance from FDA to Proceed with Phase 2 Trial of TYRA-300 in IR NMIBC
Tyra Biosciences, Inc. received FDA clearance for TYRA-300's IND, enabling a Phase 2 trial in IR NMIBC. TYRA-300, an FGFR3-selective inhibitor, targets FGFR3 alterations common in NMIBC. The SURF302 study will assess its efficacy and safety in 90 participants across the U.S., focusing on CR rate and other endpoints.
Tyra Biosciences, Inc. Receives IND Clearance from FDA to Proceed with TYRA-300's Phase 2 Trial in IR NMIBC
Tyra Biosciences received FDA clearance for TYRA-300's Phase 2 trial in IR NMIBC, led by Dr. Erik Goluboff. TYRA-300, an FGFR3-selective inhibitor, targets FGFR3 alterations common in NMIBC. The SURF302 study will assess its efficacy and safety in 90 participants across the U.S., focusing on CR rate at three months and other secondary endpoints.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Position Raised by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. increased its stake in Tyra Biosciences by 2.2% in Q3, owning 173,737 shares worth $4,085,000. Other institutional investors also adjusted their holdings. Tyra Biosciences reported a Q3 loss of $0.41 per share, missing estimates. Insiders sold shares, and analysts have mixed ratings with an average 'Buy' and target price of $31.00.
Janus Henderson Group PLC Purchases Shares of 1,067,196 Tyra Biosciences, Inc
Janus Henderson Group PLC acquired 1,067,196 shares of Tyra Biosciences, valued at $24.99M, owning 2.11% at the end of Q3. Other institutional investors also increased their stakes, with 84.14% of TYRA stock owned by institutions. Wall Street analysts forecast growth, with a consensus 'Buy' rating and an average target price of $31.00. TYRA shares opened at $15.73, with a market cap of $795.94M. CFO Alan Fuhrman purchased 9,500 shares at $16.00 each, while CEO Todd Harris sold 10,092 shares at $24.13 each.
US FDA clears Tyra Biosciences' IND application to advance TYRA-300 phase 2 trial in children with achondroplasia
Tyra Biosciences received FDA clearance for TYRA-300's phase 2 trial (BEACH301) in children with achondroplasia, aiming to improve growth velocity and functional outcomes. TYRA-300, an oral FGFR3-selective inhibitor, also shows promise in metastatic urothelial cancer. The study targets children aged 3-10, evaluating safety, tolerability, and growth changes.
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Trial for TYRA-300 in Achondroplasia
TYRA Biosciences received FDA clearance for TYRA-300, an oral FGFR3-selective inhibitor, to proceed with a Phase 2 trial (BEACH301) for achondroplasia in children, aiming for dosing in Q1 2025. TYRA-300, also under evaluation for metastatic urothelial cancer, targets FGFR3 to potentially improve growth velocity and clinical outcomes in achondroplasia, offering a novel oral treatment alternative to current therapies.
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia
Tyra Biosciences received FDA IND clearance for TYRA-300, an oral FGFR3-selective inhibitor, to proceed with a Phase 2 study (BEACH301) in pediatric achondroplasia. The study aims to assess safety, tolerability, and growth velocity changes, with dosing expected to start in Q1 2025. TYRA-300 also shows promise in metastatic urothelial cancer.
© Copyright 2025. All Rights Reserved by MedPath